Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012148047> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2012148047 abstract "Pegylated liposomal doxorubicin (PEG-LD) and docetaxel have single-agent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with advanced malignancies.Twenty-two patients were enrolled in this two-arm, accelerated, dose escalation trial. Both drugs were administered on Days 1 and 15 of a 28 day cycle. In Arm A, dose escalation proceeded from a sequence and starting dose of 15 mg/m(2) PEG-LD and 30 mg/m(2) docetaxel. In Arm B, dose escalation proceeded from a sequence and starting dose of 30 mg/m(2) docetaxel and 15 mg/m(2)PEG-LD. In both arms, the dose of each drug was increased alternately by 5 mg/m(2) at each dose level.The MTD for Arm A was 20 mg/m(2) PEG-LD and 40 mg/m(2) docetaxel, both of which were administered on Days 1 and 15 of a 28-day cycle. The MTD for Arm B was 35 mg/m(2) docetaxel and 20 mg/m(2) PEG-LD, both of which were administered on Days 1 and 15 of a 28-day cycle. Dose-limiting toxicities were Grade 3 (according to the National Cancer Institute Common Toxicity Criteria) skin toxicity and thrombocytopenia. One partial response was observed and stable disease was documented for three patients.The recommended sequence and dose is 20 mg/m(2) PEG-LD followed by 40 mg/m(2) docetaxel on Days 1 and 15 of a 28-day cycle in Phase II trials for patients with breast and ovarian carcinoma to establish the efficacy of this well tolerated regimen." @default.
- W2012148047 created "2016-06-24" @default.
- W2012148047 creator A5004726451 @default.
- W2012148047 creator A5008763534 @default.
- W2012148047 creator A5017254635 @default.
- W2012148047 creator A5034354367 @default.
- W2012148047 creator A5047292923 @default.
- W2012148047 creator A5050288292 @default.
- W2012148047 creator A5050643833 @default.
- W2012148047 creator A5068272287 @default.
- W2012148047 creator A5068824818 @default.
- W2012148047 creator A5077822463 @default.
- W2012148047 date "2003-07-18" @default.
- W2012148047 modified "2023-09-26" @default.
- W2012148047 title "Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies" @default.
- W2012148047 cites W1769308960 @default.
- W2012148047 cites W1828224642 @default.
- W2012148047 cites W1865453869 @default.
- W2012148047 cites W1918322381 @default.
- W2012148047 cites W1920828316 @default.
- W2012148047 cites W1972536070 @default.
- W2012148047 cites W2019200453 @default.
- W2012148047 cites W2053681261 @default.
- W2012148047 cites W2055892918 @default.
- W2012148047 cites W2141086589 @default.
- W2012148047 cites W2148845753 @default.
- W2012148047 cites W2159905203 @default.
- W2012148047 cites W4233628679 @default.
- W2012148047 cites W4242088004 @default.
- W2012148047 cites W4255246690 @default.
- W2012148047 doi "https://doi.org/10.1002/cncr.11547" @default.
- W2012148047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12879480" @default.
- W2012148047 hasPublicationYear "2003" @default.
- W2012148047 type Work @default.
- W2012148047 sameAs 2012148047 @default.
- W2012148047 citedByCount "13" @default.
- W2012148047 countsByYear W20121480472014 @default.
- W2012148047 countsByYear W20121480472019 @default.
- W2012148047 crossrefType "journal-article" @default.
- W2012148047 hasAuthorship W2012148047A5004726451 @default.
- W2012148047 hasAuthorship W2012148047A5008763534 @default.
- W2012148047 hasAuthorship W2012148047A5017254635 @default.
- W2012148047 hasAuthorship W2012148047A5034354367 @default.
- W2012148047 hasAuthorship W2012148047A5047292923 @default.
- W2012148047 hasAuthorship W2012148047A5050288292 @default.
- W2012148047 hasAuthorship W2012148047A5050643833 @default.
- W2012148047 hasAuthorship W2012148047A5068272287 @default.
- W2012148047 hasAuthorship W2012148047A5068824818 @default.
- W2012148047 hasAuthorship W2012148047A5077822463 @default.
- W2012148047 hasConcept C126322002 @default.
- W2012148047 hasConcept C2776694085 @default.
- W2012148047 hasConcept C2777334693 @default.
- W2012148047 hasConcept C2781190966 @default.
- W2012148047 hasConcept C29730261 @default.
- W2012148047 hasConcept C71924100 @default.
- W2012148047 hasConcept C90924648 @default.
- W2012148047 hasConcept C98274493 @default.
- W2012148047 hasConceptScore W2012148047C126322002 @default.
- W2012148047 hasConceptScore W2012148047C2776694085 @default.
- W2012148047 hasConceptScore W2012148047C2777334693 @default.
- W2012148047 hasConceptScore W2012148047C2781190966 @default.
- W2012148047 hasConceptScore W2012148047C29730261 @default.
- W2012148047 hasConceptScore W2012148047C71924100 @default.
- W2012148047 hasConceptScore W2012148047C90924648 @default.
- W2012148047 hasConceptScore W2012148047C98274493 @default.
- W2012148047 hasLocation W20121480471 @default.
- W2012148047 hasLocation W20121480472 @default.
- W2012148047 hasOpenAccess W2012148047 @default.
- W2012148047 hasPrimaryLocation W20121480471 @default.
- W2012148047 hasRelatedWork W2004920434 @default.
- W2012148047 hasRelatedWork W2039697967 @default.
- W2012148047 hasRelatedWork W2064002348 @default.
- W2012148047 hasRelatedWork W2081415890 @default.
- W2012148047 hasRelatedWork W2103960677 @default.
- W2012148047 hasRelatedWork W2155481114 @default.
- W2012148047 hasRelatedWork W2397482356 @default.
- W2012148047 hasRelatedWork W2404849105 @default.
- W2012148047 hasRelatedWork W2407247369 @default.
- W2012148047 hasRelatedWork W2751185517 @default.
- W2012148047 isParatext "false" @default.
- W2012148047 isRetracted "false" @default.
- W2012148047 magId "2012148047" @default.
- W2012148047 workType "article" @default.